GRADE 3A FOLLICULAR LYMPHOMA

This phase II trial is testing two drugs, obinutuzumab and ibrutinib, as the first treatment for people with indolent non-Hodgkin's lymphoma, a slow-growing blood cancer. The goal is to see how many patients respond to the combination. The study involves 30 participants and is no…

This phase II trial tests a combination of three drugs—acalabrutinib, lenalidomide, and rituximab—in 60 people with untreated follicular lymphoma that has spread. The goal is to see if this chemo-free mix can make the cancer disappear completely. Participants take the drugs by mo…

This early-phase study tests a combination of three drugs (obinutuzumab, venetoclax, and lenalidomide) in people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The main goal is to find the safest dose and see how well the drugs work togeth…

This study tests whether a combination of three drugs (obinutuzumab, ibrutinib, and venetoclax) can shrink tumors in people with untreated follicular lymphoma. The trial includes 40 adults with stage II to IV disease. The goal is to see if the combination works better than any si…

This study is for people with a type of slow-growing lymphoma (grades 1-3a) that has returned or not responded to earlier treatment. It tests whether adding other drugs to a standard immunotherapy (obinutuzumab) can improve results. About 73 adults will receive different treatmen…

This study tests a combination of two drugs—nivolumab and lenalidomide—in people with non-Hodgkin or Hodgkin lymphoma that has returned or stopped responding to treatment. The goal is to find the safest dose and see if the combo can shrink tumors. About 36 adults will take part i…

This study tests whether adding the drug acalabrutinib to CAR T-cell therapy (a treatment that uses a patient's own immune cells to fight cancer) is safe and effective for adults with certain types of B-cell lymphoma. About 23 participants will receive the combination. The goal i…

This study tested a drug called ibrutinib in 41 people with follicular lymphoma that returned or didn't respond to prior treatment. Ibrutinib works by blocking certain enzymes that cancer cells need to grow. The main goal was to see how many patients had their tumors shrink or di…